When tumor-infiltrating T cells were stimulated with a combination of anti-CD3 and anti-PD-1 monoclonal antibodies, the STING/IFN-γ pathway was induced and activated in lung adenocarcinomas, increasing the IFN-β and CCL5 expression, and an active IFN-γ pathway is a common feature of tumors responding to PD-1/PD-L1 blockade therapy (110). This evidence concerns the gene STING1 and lung adenocarcinoma.